Abstract Number: 5 • 2017 Pediatric Rheumatology Symposium
Effects of Puberty on Systemic Lupus Erythematosus: Results of a multi-center prospective longitudinal observational study in children entering puberty with SLE
Background/Purpose: Lupus often presents during puberty, and when it affects pre-pubertal children, disease activity is thought to increase at puberty. Sex hormones play some role…Abstract Number: 86 • 2016 ACR/ARHP Annual Meeting
Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation Between Promis Instruments for PRO Data Capture
Background/Purpose: Patient-reported outcomes (PROs) are key to enabling the comprehensive assessment of patient-centered benefits in comparative effectiveness research (CER). However, the relationships between different PROMIS…Abstract Number: 519 • 2016 ACR/ARHP Annual Meeting
Greater Fatigue at Baseline and Female Gender Predict Worse Disability in Early RA Despite Treatment to Target: A Comparison of Two Observational Cohort Studies from the United Kingdom
Background/Purpose: Although disability is part of the ‘core set’ of outcomes for RA research recommended by OMERACT (1), current therapeutic strategies focus on inflammation. The…Abstract Number: 772 • 2016 ACR/ARHP Annual Meeting
Effect of HMG-CoA Reductase Inhibitor Drugs (Statins) on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
Background/Purpose: Statins have been shown to have anti-inflammatory and immunomodulatory effects. In vitro studies show that these drugs inhibit inflammatory cells, decrease the expression of…Abstract Number: 1226 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Association Between C-Reactive Protein and Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: Analysis of Two Clinical Practice Data Sets
Background/Purpose: The association between inflammatory markers such as CRP or ESR and joint damage has been widely established in RA. Autoantibodies such as RF and…Abstract Number: 1514 • 2016 ACR/ARHP Annual Meeting
Symptoms of Depression and Anxiety Predict Worse Disease Activity and Functional Disability in a Cohort of Established Rheumatoid Arthritis Patients
Background/Purpose: Depression and anxiety disorders are common in RA patients, with the most recent prevalence estimates indicating that 16.8% of RA patients have a diagnosis…Abstract Number: 1741 • 2016 ACR/ARHP Annual Meeting
Patients with Active Psoriatic Arthritis Achieving Minimal Disease Activity with Secukinumab Treatment Demonstrate Sustained Improvement of Function and Quality of Life
Background/Purpose: Secukinumab, a fully human anti–IL-17A monoclonal antibody, previously demonstrated higher minimal disease activity (MDA)1 response rates and sustained improvements in patient reported outcomes2 among…Abstract Number: 2159 • 2016 ACR/ARHP Annual Meeting
Allopurinol Use Is Associated with Lower Risk of Peripheral Vascular Disease in the US Elderly
Background/Purpose: Gout is associated with higher cardiovascular disease risk. Based on our previous work, there is evidence that allopurinol use reduces the risk of myocardial…Abstract Number: 2578 • 2016 ACR/ARHP Annual Meeting
Plasma Levels of Bone Morphogenetic Protein (BMP) Subgroups and Their Inhibitors (noggin, sclerostin) in Rheumatoid Arthritis Patients and Correlation with Disease Activity, Clinical and Radiographic Progression
Background/Purpose: Progressive bone destruction occurs in rheumatoid arthritis (RA) due to imbalance of osteoblast/osteoclast activity. Bone morphogenetic proteins (BMPs) regenerate bone damage by stimulating the…Abstract Number: 2814 • 2016 ACR/ARHP Annual Meeting
Immunofluorescence Pattern and Titer of the Antinuclear Antibody Test Correlate with Disease Activity in Patients with Systemic Lupus Erythematosus
Background/Purpose: Antinuclear antibody (ANA) indirect immunofluorescence (IIF) assay on HEp-2 cells (HEp-2-ANA) is an important element for diagnosis and classification of Systemic Lupus Erythematosus (SLE),…Abstract Number: 3083 • 2016 ACR/ARHP Annual Meeting
Utility of Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Short Form for Understanding Interplay Between Patient-Reported Outcome Measures and Physician Driven Disease Activity Measures
Background/Purpose: Discordance between patient and physician assessment of rheumatoid arthritis (RA) disease activity strongly associates with pain scores. Patient-reported outcomes measurement information system (PROMIS) 29…Abstract Number: 115 • 2016 ACR/ARHP Annual Meeting
Early Inflammatory Arthritis Presentation, Management and Outcomes in Canadian Aboriginal Patients
Background/Purpose: Differences in access to care that influence the timing and quality of treatment interventions may create outcome inequities for Aboriginal patients with inflammatory arthritis.…Abstract Number: 522 • 2016 ACR/ARHP Annual Meeting
Patient-Provider Discordance in Global Assessments of Disease Activity in Patients with Rheumatoid Arthritis: Persistence, Predictors and Impact
Background/Purpose: Patient-provider discordance in global assessment (GA) of disease activity is a potential threat to patient-centered management of individuals with RA. The estimated prevalence of…Abstract Number: 786 • 2016 ACR/ARHP Annual Meeting
Complement Split Product iC3b and C3 Blood Levels Best Associate with Active and Clinically Meaningful Changes in SLE Disease Activity
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…Abstract Number: 1331 • 2016 ACR/ARHP Annual Meeting
Disease Patterns and Long Term Outcome Amongst Patients with Relapsing Polychondritis – Single Centre Experience
Background/Purpose: Relapsing polychondritis (RP) is a rare autoimmune disorder characterized by cartilage inflammation and damage. Chronic RP may lead to sequelae due to cartilage tissue…
- « Previous Page
- 1
- …
- 66
- 67
- 68
- 69
- 70
- …
- 102
- Next Page »